Filing Details

Accession Number:
0001493152-24-039081
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-10-01 21:27:33
Reporting Period:
2024-09-26
Accepted Time:
2024-10-01 21:27:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1641631 Beyond Air Inc. XAIR Surgical & Medical Instruments & Apparatus (3841) 473812456
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1702628 A. Steven Lisi C/O Beyond Air, Inc.
900 Stewart Avenue, Suite 301
Garden City NY 11530
Ceo And Chairman Of The Board Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-26 1,476,626 $0.50 3,249,411 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Pre-funded Warrants to purchase Common Stock Acquisiton 2024-09-26 506,321 $0.00 506,321 $0.00
Common Stock Warrants to purchase Common Stock Acquisiton 2024-09-26 1,982,947 $0.00 1,982,947 $0.38
Common Stock Warrants to purchase Common Stock Acquisiton 2024-09-27 3,295,544 $0.00 3,295,544 $0.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
506,321 No 4 P Direct
1,982,947 No 4 P Direct
3,295,544 No 4 J Direct
Footnotes
  1. Pursuant to a Securities Purchase Agreement (the "Agreement"), dated as of September 26, 2024, by and between Beyond Air, Inc. (the "Issuer") and Steven Lisi (the "Reporting Person"), the Reporting Person acquired in a private placement transaction 1,476,626 shares of common stock, $0.0001 par value per share (the "Common Stock"), pre-funded warrants to acquire 506,321 shares of Common Stock at an exercise price of $0.0001 per share, and common warrants to acquire 1,982,947 shares of Common Stock at an exercise price of $0.3793 per share.
  2. The pre-funded warrants will be exercisable on or after the date on which the Company obtains stockholder approval (the "Initial Exercise Date"), as further described in the Agreement and in the Issuer's Current Report on Form 8-K filed with the SEC on September 27, 2024, and shall expire when exercised in full.
  3. Each pre-funded warrant was purchased with an accompanying warrant for a purchase price of $0.5042 per pre-funded warrant and accompanying warrant.
  4. The common warrants are exercisable on or after the Initial Exercise Date and will have a term that expires five years following the Initial Exercise Date.
  5. Each common share was purchased with an accompanying warrant for a purchase price of $0.5043 per share and accompanying warrant.
  6. Pursuant to a binding term sheet dated as of September 27, 2024 in connection with a loan to the Issuer of $2,500,000, the Reporting Person acquired warrants to purchase up to 3,295,544 shares of Common Stock.
  7. The warrants issuable will be exercisable on or after the Initial Exercise Date and will expire five years following such date they are exercisable.